Posology : מינונים

4.2 Posology and method of administration

As directed by a physician. Dosage is dependent upon the age, weight, and clinical condition of the patient as well as laboratory determinations.
The dosage and constant infusion rate of intravenous Sodium Chloride 0.45 % and Glucose 5.0 % Solution for Infusion Baxter must be selected with caution in pediatric patients, particularly neonates and low weight infants, because of the increased risk of hyperglycemia/hypoglycemia.
The infusion rate and volume depend on the age, weight, clinical and metabolic conditions of the patient, concomitant therapy and should be determined by the consulting physician experienced in pediatric intravenous fluid therapy.
Precautions to be taken before manipulating or administering the product 

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. Do not administer unless solution is clear, and seal is intact.
Administer immediately following the insertion of infusion set. Do not remove unit from overwrap until ready for use. The inner bag maintains the sterility of the product.
All injections in plastic containers are intended for intravenous administration using sterile equipment and aseptic technique. Sodium Chloride 0.45 % And Glucose 5 % Solution for Infusion Baxter is hypotonic and hyperosmolar, due to the glucose content. It has an approximate osmolarity of 432 mOsm/l.
The equipment should be primed with the solution in order to prevent air entering the system.
Do not use plastic containers in series connections. Such use could result in air embolism due to residual air being drawn from the primary container before the administration of the fluid from the secondary container is completed.
Pressurizing intravenous solutions contained in flexible plastic containers to increase flow rates can result in air embolism if the residual air in the container is not fully evacuated prior to administration. Use of a vented intravenous administration set with the vent in the open position could result in air embolism. Vented intravenous administration sets with the vent in the open position should not be used with flexible plastic containers.
Additives may be incompatible. Complete information is not available.
Those additives known to be incompatible should not be used. Consult with pharmacist, if available. If, in the informed judgment of the physician, it is deemed advisable to introduce additives, use aseptic technique.
Additives may be introduced before or during infusion through the resealable medication port.
When additive is used, verify tonicity prior to parenteral administration. Hyperosmolar solutions may cause venous irritation and phlebitis. Thus, any hyperosmolar solution is recommended to be administered through a large central vein, for rapid dilution of the hyperosmotic solution.
Mix thoroughly when additives have been introduced. Do not store solutions containing additives.
For further information on the product with additives, please see sections 6.2, 6.3 and 6.6.